Irodalom:
1. Gockel I, Kneist W, Junginger T.: Incurable esophageal cancer: patterns of tumor spread and therapeutic
consequences. World J Surg. 2006 Feb;30(2):183-90.
2. Koishi K, Yoshikawa R, Tsujimura T, Hashimoto-Tamaoki T,Kojima SYanagi Yamamura T, Fujiwara Y.:
Persistent CXCR4 expression after preoperative chemoradiotherapy predicts early recurrence and poor
prognosis in esophageal cancer. World J Gastroenterol. 2006 Dec 21;12(47):7585-90.
3. Fiore D, Baggio V, Ruol A, Bocus P, Casara D, Corti L, Muzzio PC.: Multimodal imaging of esophagus
and cardia cancer before and after treatment. Radiol Med (Torino). 2006 Sep;111(6):804-17. Epub 2006 Aug 11
4. Oehler C, Ciernik IF.: Radiation therapy and combined modality treatment of gastrointestinal carcinomas.
Cancer Treat Rev. 2006 Apr;32(2):119-38. Epub 2006 Mar 9.
5. Duong CP, Hicks RJ, Weih L, Drummond E, Leong T, Michael M, Thomas RJ.: FDG-PET status following
chemoradiotherapy provides high management impact and powerful prognostic stratification in
oesophageal cancer. Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):770-8.
74 Gastro Update 2007
6. Wang XS, Liu MZ, Zhang CQ, Cai L, Cui NJ.: Effect of concurrent chemoradiotherapy on serum vascular
endothelial growth factor in esophageal squamous cell carcinoma patients — a report of 43 cases. Ai
Zheng. 2006 Nov;25(11):1428-32.
7. Nakamura T, Ota M, Hayashi K, Eguchi R, Ide H, Takasaki K, Mitsuhashi N.: Chemoradiotherapy with
and without esophagectomy for advanced esophageal cancer. Hepatogastroenterology. 2006 SepOct;53(71):705-9.
8. Osaka Y, Takagi Y, Hoshino S, Tachibana S, Tsuchida A, Aoki T.: Combination chemotherapy with docetaxel
and nedaplatin for recurrent esophageal cancer in an outpatient setting. Dis Esophagus. 2006;19(6):473-6.
9. Ott K, Weber W, Siewert JR.: The importance of PET in the diagnosis and response evaluation of
esophageal cancer. Dis Esophagus. 2006;19(6):433-42
10. Ilson DH.: Cancer of the gastroesophageal junction: combined modality therapy.Surg Oncol Clin N
Am. 2006 Oct;15(4):803-24.
11. Tsujimoto H, Ono S, Chochi K, Sugasawa H, Ichikura T, Mochizuki H.: Preoperative chemoradiotherapy
for esophageal cancer enhances the postoperative systemic inflammatory response. Jpn J Clin Oncol.
2006 Oct;36(10):632-7. Epub 2006 Oct 4.
12. Motoyama S, Sugiyama T, Okamoto H, Takasawa S, Nanjo H, Watanabe HMaruyama K, Okuyama M,
Ogawa J.: REG I expression predicts long-term survival among locally advanced thoracic squamous
cell esophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by esophagectomy.
Ann Surg Oncol. 2006 Dec;13(12):1724-31. Epub 2006 Sep 30.
13. Lagarde SM, ten Kate FJ, Reitsma JB, Busch OR, vannschot JJ.: Prognostic factors in adenocarcinoma
of the esophagus or gastroesophageal junction. Oncol. 2006 Sep 10;24(26):4347-55.
14. Di Fiore F, Lecleire S, Rigal O, Galais MP, Ben Soussan E, David I, Paillot B, Jacob JH, Michel P.:
Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell
esophageal carcinoma. World J Gastroenterol. 2006 Jul 14;12(26):4185-90.
15. Lerut T, Coosemans W, Decker G, De Leyn P, Moons J, Nafteux P, Van Raemdonck D.: Diagnosis and
therapy in advanced cancer of the esophagus and the gastroesophageal junction. Curr Opin Gastroenterol.
2006 Jul;22(4):437-41
16. Kodaira T, Fuwa N, Kamata M, Furutani K, Tachibana H, Yamazaki T.: Single-institute phase I/II trial
of alternating chemoradiotherapy with 5-FU and nedaplatin for esophageal carcinoma. Anticancer Res.
2006 Jan-Feb;26(1B):471-8.
17. Rohatgi PR, Correa AM, Swisher SG, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Lee JH,
Rice DC, Roth JA, Ajani JA.: Gender-based analysis of esophageal cancer patients undergoing preoperative
chemoradiation: differences in presentation and therapy outcome. Dis Esophagus. 2006;19(3):152-7.
18. Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC,
Bresalier RS, Roth JA, Ajani JA.: Histologic subtypes as determinants of outcome in esophageal carcinoma
patients with pathologic complete response after preoperative chemoradiotherapy. Cancer. 2006 Feb 1;
106(3):552-8.
19. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell
esophageal carcinoma.
20. Di Fiore F, Lecleire S, Rigal O, Galais MP, Ben Soussan E, David I, Paillot B, Jacob JH, Michel P.:
World J Gastroenterol. 2006 Jul 14;12(26):4185-90.
21. Reynolds JV, McLaughlin R, Moore J, Rowley S, Ravi N.: Prospective evaluation of quality of life in
patients with localized oesophageal cancer treated by multimodality therapy or surgery alone. Br J
Surg. 2006 Sep;93(9):1084-90.
22. Zhang SC, Hironaka S, Ohtsu A, Yoshida S, Hasebe T, Fukayama M, Ochiai A.: Computer-assisted
analysis of biopsy specimen microvessels predicts the outcome of esophageal cancers treated with
chemoradiotherapy. Clin Cancer Res. 2006 Mar 15;12(6):1735-42.
23. Duong CP, Hicks RJ, Weih L, Drummond E, Leong T, Michael M, Thomas RJ.: FDG-PET status following
A nyelõcsõ 75
chemoradiotherapy provides high management impact and powerful prognostic stratification in
oesophageal cancer. Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):770-8.
24. Yamada K, Murakami M, Okamoto Y, Okuno Y, Nakajima T, Kusumi F, Takakuwa H, Matsusue S.:
Treatment results of chemoradiotherapy for clinical stage I (T1N0M0) esophageal carcinoma. Int J
Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1106-11.
25. Mariette C, Piessen G, Lamblin A, Mirabel X, Adenis A, Triboulet JP.: Impact of preoperative
radiochemotherapy on postoperative course and survival in patients with locally advanced squamous
cell oesophageal carcinoma. Br J Surg. 2006 Sep;93(9):1077-83.
26. Siewert JR, Ott K.: Are squamous and adenocarcinomas of the esophagus the same disease? Semin
Radiat Oncol. 2007 Jan;17(1):38-44.
27. Adams R, Morgan M, Mukherjee S, Brewster A, Maughan T, Morrey DClark GRoberts S,Vachtsevanos L,
Leong J, Hardwick R, Carey D, Crosby T.: A prospective comparison of multidisciplinary treatment of
oesophageal cancer with curative intent in a UK cancer network. Eur J Surg Oncol. 2006 Nov 21;
28. Wong R, Malthaner R.: Combined chemotherapy and radiotherapy (without surgery) compared with
radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev. 2006 Jan 25;(1)
29. Nakamura T, Ota M, Hayashi K, Eguchi R, Ide H, Takasaki K, Mitsuhashi N.: Chemoradiotherapy with
and without esophagectomy for advanced esophageal cancer. Hepatogastroenterology. 2006 Sep-Oct;
53(71):705-9.
30. Osaka Y, Takagi Y, Hoshino S, Tachibana S, Tsuchida A, Aoki T: Combination chemotherapy with docetaxel
and nedaplatin for recurrent esophageal cancer in an outpatient setting. Dis Esophagus. 2006;19(6):473-6.
31. Henry LR, Goldberg M, Scott W, Konski A, Meropol NJ, Freedman G, Weiner LM Watts Beard M,
McLaughlin S, Cheng JD.: Induction cisplatin and paclitaxel followed by combination chemoradiotherapy
with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II
report. Ann Surg Oncol. 2006 Feb;13(2):214-20. Epub 2006 Jan 18.
32. Hofstetter WL, Correa AM, Ajani JA, Komaki RR, Rice DC, Vaporciyan AA, Walsh GL,Roth JA, Wu TT,
Swisher SG.: The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy
improves tumor response in patients with esophageal adenocarcinoma. Cancer. 2006 Sep 1;107(5):967-74.
33. Kim DW, Blanke CD, Wu H, Shyr Y, Berlin J, Beauchamp RD, Chakravarthy B.: Phase II study of
preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer. Int J Radiat
Oncol Biol Phys. 2007 Feb 1;67(2):397-404. Epub 2006 Nov.
34. Dawson SJ, Michael M, Biagi J, Foo KF, Jefford M, Ngan SY, Leong T, Hui A, Milner AD,Thomas
RJ, Zalcberg JR: A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of
patients with locally advanced oesophageal cancer. Invest New Drugs. 2007 Apr;25(2):123-9. Epub
2006 Oct 20.
35. Geh JI, Bond SJ, Bentzen SM, Glynne-Jones R.: Sysstematic overview of preoperative (neoadjuvant)
chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose
response. Radiother Oncol. 2006 Mar;78(3):236-44. Epub 2006 Mar 20.
36. Reynolds JV, McLaughlin R, Moore J, Rowley S, Ravi N, Byrne PJ.: Prospective evaluation of quality
of life in patients with localized oesophageal cancer treated by multimodality therapy or surgery alone.
Br J Surg. 2006 Sep;93(9):1084-90.
37. Kumekawa Y, Kaneko K, Ito H, Kurahashi T, Konishi K, Katagiri A, Yamamoto T,Kuwahara M, Kubota Y,
Muramoto T, Mizutani Y, Imawari M.: Late toxicity in complete response cases after definitive
chemoradiotherapy for esophageal squamous cell carcinoma. J Gastroenterol. 2006 May;41(5):425-32.
38. Wang KL, Yang Q, Cleary KR, Swisher SG, Correa AM, Komaki R, Ajani JA, Rashid A, Hamilton SR,
Wu TT.: The significance of neuroendocrine differentiation in adenocarcinoma of the esophagus and
esophagogastric junction after preoperative chemoradiation. Cancer. 2006 Oct 1;107(7):1467-74.
39. Wu TT, Chirieac LR, Abraham SC, Krasinskas AM, Wang H, Rashid A, Correa AM, Hofstetter WL,
Ajani JA, Swisher SG.: Excellent interobserver agreement on grading the extent of residual carcinoma
76 Gastro Update 2007
after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable
predictor for patient outcome. Am J Surg Pathol. 2007 Jan;31(1):58-64.
40. Gu Y, Swisher SG, Ajani JA, Correa AM, Hofstetter WL, Liao Z, Komaki RR, Rashid A,Hamilton SR,
Wu TT.: The number of lymph nodes with metastasis predicts survival in patients with esophageal or
esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer. 2006 Mar 1;
106(5):1017-25.
41. Hofstetter WL, Correa AM, Ajani JA, Komaki RR, Rice DC, Vaporciyan AA, Walsh GL,Roth JA, Wu TT,
Swisher SG.: The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy
improves tumor response in patients with esophageal adenocarcinoma. Cancer. 2006 Sep 1;107(5):967-74.
42. Toh Y, Ohga T, Itoh S, Kabashima A, Yamamoto K, Adachi E, Sakaguchi Y, Okamura T, Hirata H.:
Treatment results of radical surgery and definitive chemoradiotherapy for patients with submucosal
esophageal squamous cell cancinomas. Anticancer Res. 2006 May-Jun;26(3B):2487-91.
43. Chao KS.: Functional Imaging for Early Prediction of Response to Chemoradiotherapy: 3’-deoxy-3’-
(18)F-fluorothymidine Positron Emission Tomography — A Clinical Application Model of Esophageal
Cancer. Semin Oncol. 2006 Dec;33 Suppl 11:59-63.
44. A. U. Pande, R. Iyer, H. Nava, G. Yang, C. Nwogu, M. Schiff, C. Levea, J. Black, M. Javle: Gefitinib
(ZD1839) with oxaliplatin and radiotherapy (RT) for esophageal carcinoma (EC). Gastrointestinal
Cancer Symposium 2007, Abstr. 68.
45. C. P. Bowen-Wells, B. Ardalan, S. Spector, A. Livingstone, D. Franceschi, M. Lima, L. Sparling, E.
Avisar, G. Walker, P. Ganjei-Azar: Neoadjuvant and adjuvant chemotherapy without radiation for
esophageal cancer. Gastrointestinal Cancer Symposium 2007. Abstr.66.
46. M. S. Beg, R. S. Komrokji, M. Atiq, S. Ali, S. F. Mekan, A. Gupta, P.: John, M. M. Safa: Esophageal
cancer at the VA: Does histology matter? Gastrointestinal Cancer Symposium 2007Abstr.61
47. Phase II study of neoadjuvant chemotherapy with docetaxel, capecitabine and cisplatin (DXP) in
patients with locally advanced unresectable or intra-abdominal metastatic gastric cancer.
Gastrointestinal Cancer Symposium 2007.65.
48. Henry LR, Goldberg M, Scott W, Konski A, Meropol NJ, Freedman G, Weiner LM, Watts P, Beard M,
McLaughlin S, Cheng JD.: Induction cisplatin and paclitaxel followed by combination chemoradio
therapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a
phase II report. Ann Surg Oncol. 2006 Feb;13(2):214-20. Epub 2006 Jan 18.
49. Darling G,Eton DT,Dulman J,Casson AG,Celia D.: Validation of the functional assessment of cancer
therapy esophageal cancer subscale. Cancer. 2006 Aug 15;107(4):854-63.
50. Katsoulis Ie,Karoon A,Mylvaganam S,Livingstone J.: Endoscopic palliation of malignant dysphagia: a
challenging task in inoperableoesophageacancer. World J Surg Oncol. 2006 Jul 4;4:38.
